Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.90 |
| ▸ | TYMS | P04818 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | TLR4 | O00206 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.63 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | GART | P22102 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056952 | 1.00 | DHFR (0.90) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL24413577 | 0.92 | DHFR (0.77) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL24413580 | 0.92 | DHFR (0.77) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL6337570 | 0.92 | DHFR (0.77) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL10820237 | 0.87 | DHFR (0.72) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL10848540 | 0.87 | DHFR (0.72) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL9446115 | 0.84 | DHFR (0.75) | DHFRFOLR2FOLR1GARTSLC19A1 | |
| SCHEMBL9892511 | 0.84 | DHFR (0.75) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL12153090 | 0.83 | DHFR (0.75) | DHFRTYMSKDM4ETLR4MEN1 | |
| SCHEMBL29711367 | 0.83 | DHFR (0.89) | DHFRTYMSGARTATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797417-B1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20150216167-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | HEINRICH HEINE UNIVERSITAT DUSSELDORF (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2797417-A1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | Heinrich-Heine-Universität Düsseldorf (DE) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013093007-A1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | HEINRICH HEINE UNIVERSITÄT DÜSSELDORF (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | DHFR 131/4885TYMS 2358/4885KDM4E 3072/4885 |
| US-20150216167-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | CBR3, GRHPR, PCK1 | DHFR 703/4885TYMS 2262/4885KDM4E 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.